ABSTRACT
Small cell lung cancer [SCLC] accounts for approximately 20% of all patients with lung cancer. Limited-disease [LD] is considered potentially curable. The role of prophylactic cranial irradiation [PCI] in those patients who achieved a complete cure [CR] to induction therapy remains uncertain. Eligible patients were randomized to receive either high dose PCI [20 patients received 2.4 Gy once daily in 10 fractions for a total dose of 24 Gy] or a standard dose PCI [25 patients were treated with 2 Gy once daily in 18 fractions for a total dose of 36 Gy, while there was another group [15 patents] who refused PCI. Results: The results confirmed the observable reduction of brain metastases with the high dose PCI compared to the standard dose PCI and also for those who did not receive PCI [16%, 35%, and 53% respectively]. Also this result confirmed the loss of significant survival advantage between those who receive PI and those who did not. No evidence of consistent difference regarding neurological and cognitive impairment between patients given or not PCI